0001725160-21-000163.txt : 20210706 0001725160-21-000163.hdr.sgml : 20210706 20210706200108 ACCESSION NUMBER: 0001725160-21-000163 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210701 FILED AS OF DATE: 20210706 DATE AS OF CHANGE: 20210706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Epperly Melissa B, CENTRAL INDEX KEY: 0001807359 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39263 FILM NUMBER: 211075920 MAIL ADDRESS: STREET 1: C/O ZENTALIS PHARMACEUTICALS, INC. STREET 2: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001725160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (212) 433-3791 MAIL ADDRESS: STREET 1: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC DATE OF NAME CHANGE: 20200107 FORMER COMPANY: FORMER CONFORMED NAME: Zeno Pharma, LLC DATE OF NAME CHANGE: 20171212 4 1 wf-form4_162561605028744.xml FORM 4 X0306 4 2021-07-01 0 0001725160 Zentalis Pharmaceuticals, Inc. ZNTL 0001807359 Epperly Melissa B, C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 0 1 0 0 Chief Financial Officer Common Stock 2021-07-01 4 S 0 700 50.1043 D 259457 D Common Stock 2021-07-01 4 S 0 1378 51.1461 D 258079 D Common Stock 2021-07-01 4 S 0 805 52.0062 D 257274 D Common Stock 2021-07-01 4 S 0 200 53.185 D 257074 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.68 to $50.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.71 to $51.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.83 to $52.39. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $53.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. By: /s/ Melissa B. Epperly 2021-07-06